Ivabradine effect on ventricular rate in non-paroxysmal atrial fibrillation patients

Phase 3

Recruiting

• Conditions: Persistent atrial fibrillation; I48.1; Atrial fibrilation.

• Registration Number: IRCT20191230045950N2
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 2 May 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Non-paroxysmal atrial fibrillation at randomization, with no prospect of cardioversion, anti arrhythmic treatment with group I or III drugs, or pulmonary vein ablation
Beta-blocker or nondihydropyridine calcium channel blocker or digoxin therapy at the maximum dose recommended for or tolerated by the patient
Ventricular rate of more than 70
Be able to voluntarily give informed consent

Exclusion Criteria

Medical causes that explain poor heart rate control: fever, anemia, hyperthyroidism ,etc
Patients with a known contraindication to Ivabradine
Valve disease requiring surgical or percutaneous repair
Impossibility to attend the visits scheduled in the protocol

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ventrical rate in non-paroxysmal atrial fibrillation patients. Timepoint: Before and one month after intervention. Method of measurement: 24 hours ambulatory heart rhythm monitoring.

Secondary Outcome Measures

Name	Time	Method
Mean daytime ventricular rate. Timepoint: Before and one month after intervention. Method of measurement: 24 hours ambulatory heart rhythm monitoring.;Mean night time ventricular rate. Timepoint: Before and one month after intervention. Method of measurement: 24 hours ambulatory heart rhythm monitoring.